Investor Relations
NASDAQ: current stock price
| Price | $30.35 |
|---|---|
| Volume | 462,053 |
| Intraday High | $31.00 |
| Intraday Low | $30.13 |
| Today's Open | $30.30 |
press releases
Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Mee...
MoreNCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newl...
MoreNovocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer ...
MoreNovocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update
MoreJAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survi...
MoreNovocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue
MoreJAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide ...
MoreNovocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancr...
MoreNovocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed ...
MorePatients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in N...
MoreNovocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research a...
MoreNovocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of T...
MoreNovocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechan...
MoreNovocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Ne...
MoreCombination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Di...
MoreNovocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual...
MoreGerman Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for ...
MoreNovocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide...
MoreData on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conferenc...
MoreNovocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European S...
MoreNovocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference
More
events
Novocure at the Deutsche Bank 43rd Annual Health Care Conference
View Presentation Listen to WebcastNovocure at the Nasdaq 37th International Investor Conference
Listen to WebcastNovocure at the Global Mizuho Investor Conference
View PresentationNovocure at the 19th Annual Rodman & Renshaw Global Investment Conference
View Presentation Listen to WebcastNovocure at the Wells Fargo 2017 Healthcare Conference
Listen to WebcastNovocure at the Bio€quity Europe 2017 Conference
View PresentationNovocure at the Deutsche Bank 42nd Annual Health Care Conference
View Presentation Listen to WebcastNovocure Research and Development Day
View Presentation
stock information
See our current stock performance, trading data and historical pricing information (NASDAQ: NVCR).
Learn More
FAQs
- What is the ticker symbol for Novocure?
Shares of Novocure are traded on the NASDAQ Global Select Stock Market under the ticker symbol NVCR.
- When did Novocure go public?
Novocure started trading publicly on October 2, 2015.
- Where is Novocure's corporate headquarters?
Novocure is headquartered in the Bailiwick of Jersey.
- When does Novocure's fiscal year end?
December 31.
- Who is Novocure's transfer agent?
Our transfer agent is Computershare Shareowner Services LLC. There are a number of ways to contact Computershare to access information in connection with your account. Note: you will need to supply your tax identification number and contact information, including address.
Investor Centre™ website:
Manage your account online via Computershare’s secure Web-based shareholder tool at http://www.computershare.com/investor. Through free, around-the-clock access to the website, you can:
- View your account details and update account information
- Access tax forms
- Request certificates
- Enroll in eDelivery to receive shareholder materials electronically
Telephone inquiries:
+1 (877) 373-6374 (US, Canada, Puerto Rico)
+1 (781) 575-3100 (non-US)Written requests:
By regular mail:
Computershare
P.O. Box 43070
Providence, RI 02940-3070By overnight delivery:
Computershare
250 Royall Street
Canton, MA 02021- How do I change the address on my stockholder account?
If you own shares through a brokerage firm, you need to contact that firm directly to change your account address.
If you own shares in the form of a stock certificate, you may update your address by contacting our transfer agent, Computershare Shareowner Services LLC, at 877-419-8459 or via their website at https://www-us.computershare.com/investor.
- How can I buy Novocure stock?
Shares can be purchased through a stockbroker of your choice. Novocure does not have a direct stock purchase program.
- What is Novocure's CUSIP number?
Our ordinary shares CUSIP number is G6674U 108.
- Who are the independent auditors?
Kost Forer Gabbay & Kasierer
A member of Ernst & Young Global
Tel-Aviv, Israel
sign up for email alerts
To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.
-
about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
- our therapy
-
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
- patient-forward
- news and media
- investor relations
- careers